Thread- Reinforced Encapsulation Devices (THRED) for Therapeutic Stem Cell Delivery.

IF 2.5 2区医学 Q1 PEDIATRICS

Journal of pediatric surgery Pub Date : 2026-05-06 DOI:10.1016/j.jpedsurg.2026.163196

Fikir M Mesfin, Jasmine Lee, Sharon Joseph, Krishna Manohar, Chelsea E Hunter, W Christopher Shelley, John P Brokaw, Guanglon Jiang, Jianyun Liu, Chang-Hyun Gil, Minglin Ma, Troy A Markel

{"title":"Thread- Reinforced Encapsulation Devices (THRED) for Therapeutic Stem Cell Delivery.","authors":"Fikir M Mesfin, Jasmine Lee, Sharon Joseph, Krishna Manohar, Chelsea E Hunter, W Christopher Shelley, John P Brokaw, Guanglon Jiang, Jianyun Liu, Chang-Hyun Gil, Minglin Ma, Troy A Markel","doi":"10.1016/j.jpedsurg.2026.163196","DOIUrl":null,"url":null,"abstract":"Introduction: Mesenchymal stem cells (MSCs) have been studied as potential therapeutic agents for various diseases. However, their widespread application has been limited, in part, due to the concern for tumorigenic transformation and lack of longevity in host environments secondary to immune-mediated destruction. Therefore, we set out to study an MSC encapsulation and delivery method with potential application in the treatment of intestinal ischemic diseases.Method: Human vertebra bone adherent mesenchymal stem cells (vBA-MSCs) were encapsulated in an alginate-derived Thread Reinforced Encapsulation Device (THRED). The encapsulated cells were then tested for viability, ability to retain cell surface markers, and ability to synthesize and release cytokines. Furthermore, a mouse ischemia-reperfusion model was used to test the therapeutic potential of encapsulated MSCs.Results: vBA-MSCs were successfully packaged in the experimental cell encapsulation device. Encapsulated MSCs remained viable and functional while retaining their cell surface markers. Furthermore, encapsulated MSCs improved mouse intestinal injury scores following intestinal ischemia and reperfusion injury.Discussion: The THRED is a viable option to deliver mesenchymal stem cells during therapy. Further studies are needed to elucidate the ideal number of cells and the length of time needed to deliver optimal therapy.","PeriodicalId":16733,"journal":{"name":"Journal of pediatric surgery","volume":" ","pages":"163196"},"PeriodicalIF":2.5000,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pediatric surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jpedsurg.2026.163196","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Mesenchymal stem cells (MSCs) have been studied as potential therapeutic agents for various diseases. However, their widespread application has been limited, in part, due to the concern for tumorigenic transformation and lack of longevity in host environments secondary to immune-mediated destruction. Therefore, we set out to study an MSC encapsulation and delivery method with potential application in the treatment of intestinal ischemic diseases.

Method: Human vertebra bone adherent mesenchymal stem cells (vBA-MSCs) were encapsulated in an alginate-derived Thread Reinforced Encapsulation Device (THRED). The encapsulated cells were then tested for viability, ability to retain cell surface markers, and ability to synthesize and release cytokines. Furthermore, a mouse ischemia-reperfusion model was used to test the therapeutic potential of encapsulated MSCs.

Results: vBA-MSCs were successfully packaged in the experimental cell encapsulation device. Encapsulated MSCs remained viable and functional while retaining their cell surface markers. Furthermore, encapsulated MSCs improved mouse intestinal injury scores following intestinal ischemia and reperfusion injury.

Discussion: The THRED is a viable option to deliver mesenchymal stem cells during therapy. Further studies are needed to elucidate the ideal number of cells and the length of time needed to deliver optimal therapy.

查看原文本刊更多论文

用于治疗性干细胞输送的螺纹强化封装装置（THRED）。

间充质干细胞（MSCs）已被研究为多种疾病的潜在治疗药物。然而，它们的广泛应用受到限制，部分原因是由于对致瘤性转化的担忧以及免疫介导破坏继发于宿主环境中的寿命不足。因此，我们着手研究一种具有潜在应用于肠道缺血性疾病治疗的MSC包封和递送方法。方法：将人椎体骨贴壁间充质干细胞（vBA-MSCs）包封在海藻酸盐衍生的螺纹强化包封装置（THRED）中。然后测试包被细胞的活力、保留细胞表面标记的能力以及合成和释放细胞因子的能力。此外，采用小鼠缺血-再灌注模型来测试包封MSCs的治疗潜力。结果：vBA-MSCs在实验细胞包封装置中包封成功。被封装的间充质干细胞在保留其细胞表面标记物的同时保持活力和功能。此外，包封的MSCs可改善小鼠肠缺血再灌注损伤后的肠损伤评分。讨论：THRED是治疗期间传递间充质干细胞的可行选择。需要进一步的研究来阐明理想的细胞数量和提供最佳治疗所需的时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of pediatric surgery 医学-外科

CiteScore

1.10

自引率

12.50%

发文量

569

审稿时长

38 days

期刊介绍： The journal presents original contributions as well as a complete international abstracts section and other special departments to provide the most current source of information and references in pediatric surgery. The journal is based on the need to improve the surgical care of infants and children, not only through advances in physiology, pathology and surgical techniques, but also by attention to the unique emotional and physical needs of the young patient.